Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Study of JR-131 in Renal Anemia
NCT02912533Phase 3Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Sep 2016
- Primary completion
- Mar 2018
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of darbepoetin alfa in anemia of chronic kidney disease, sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Adverse Events at 52 weeks. Started Sep 2016; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT02912533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912533.